Cell signaling news
Here we present recent news items specially selected from Nature, Nature Medicine and Nature Biotechnology.
September 2005
2005:
December |
November |
October |
September |
August |
July |
June |
May |
April |
March |
February |
January
Other years: 2002 | 2003 | 2004 | 2006 | 2007 | 2008 | 2009 | 2010
News | News in brief | News Features
News
Scientists unite in bid to drive policy
Scientist-led political action committees, or PACs, aim to influence policies on stem-cell research.
Nature (29 September 2005)
| Full Text |
Use of NIH funds placed under a spotlight
Congressman wants to know whether biomedical researchers funded by the US National Institutes of Health (NIH) are spending their grants wisely.
Nature (29 September 2005)
| Full Text |
Pioneering HIV treatment would use interference and gene therapy
Scientists have unveiled ambitious plans to test an HIV treatment based on RNAi and gene therapy.
Nature (29 September 2005)
| Full Text |
Political deadlock leaves scientists frustrated
While Germany's political parties struggle to set up a new government, scientists are left with little hope for more flexible regulations on stem-cell and biotechnology research.
Nature (29 September 2005)
| Full Text |
Cancer chief embraces top drugs job
Andrew von Eschenbach, director of the National Cancer Institute takes on additional role at embattled US Food and Drug Administration (FDA).
Nature (29 September 2005)
| Full Text |
School board in court over bid to teach intelligent design
Parents in Pennsylvania fight decision to include intelligent creator in science lessons.
Nature (29 September 2005)
| Full Text |
Brain imaging ready to detect terrorists, say neuroscientists
MRI scans can reveal when a person is lying and researchers claim they are now reliable enough to identify criminals.
Nature (22 September 2005)
| Full Text |
Flu researchers slam US agency for hoarding data
Influenza researchers are complaining that the poor sharing of data by the US disease-control agency is hindering their work.
Nature (22 September 2005)
| Full Text |
Industry money skews drug overviews
Further evidence has emerged that money from the pharmaceutical industry is distorting the medical literature.
Nature (22 September 2005)
| Full Text |
Lack of lab notes casts doubt on RNA researcher's results
A respected Japanese scientist who failed to produce laboratory notebooks confirming his published results now faces a furore over the credibility of his findings.
Nature (22 September 2005)
| Full Text |
New Orleans researchers fight to salvage work from submerged labs
Hurricane Katrina has devastated research laboratories and has made scientists question how prepared academic institutions ought to be for natural disasters.
Nature (15 September 2005)
| Full Text |
Free mice herald launch of Asia–Pacific network
Developmental biologists in Asia–Pacific countries have come up with an intriguing incentive to improve regional ties — giving away transgenic mice for free.
Nature (15 September 2005)
| Full Text |
UK embryo licence draws global attention
Scientists in Britain have been granted permission to perform controversial experiments that will create human embryos using genetic material from three people.
Nature (15 September 2005)
| Full Text |
Conflicting signals on US accelerated approvals
While the FDA waits for someone to come up with a plan to improve the accelerated approval program, some argue that as it is, drugs are not getting to the people who need them.
Nature Biotechnology (September 2005)
| Full Text |
Europe caught in innovation quagmire
As new drug approval rates drop in Europe compared to the US, the EU Commission plans to spur innovation by doubling financial support for the biotech industry.
Nature Biotechnology (September 2005)
| Full Text |
Mexico launches bold genome project
Mexico's genomic researchers believe a mestizo "hapmap" might reveal a genetic basis for some of the nation's health problems, although they are mindful of the potential for the misuse of personal genetic information.
Nature Biotechnology (September 2005)
| Full Text |
Materials exchange deal meager boost to India's biotech
The Indian biotechnology industry is trying to get beyond being a service industry, but the cost of materials and of getting regulatory approval could confound such efforts.
Nature Biotechnology (September 2005)
| Full Text |
Health centres and labs left reeling by Katrina
In the aftermath of last week's hurricane, scientists from research facilities and medical centres in the area are counting the cost — to patients, buildings and their research.
Nature (8 September 2005)
| Full Text |
Budget plans hint at lean times ahead for Japanese research
Basic research in life sciences may face cutbacks as the government wants to focus on large-scale projects such as space missions and supercomputers.
Nature (8 September 2005)
| Full Text |
Drug firms vow to tone down consumer advertisements
Facing increased scrutiny of drug ads, companies announce voluntary measures.
Nature Medicine (September 2005)
| Full Text |
Loss of grants review board leaves Australian scientists wary
The Australian Research Council plans to dissolve the grant review board to expedite approval, a move scientists say will leave the process vulnerable to political whim.
Nature Medicine (September 2005)
| Full Text |
Skeptics demand duplication of controversial fertility claim
Finding that stem cells in the bone marrow can regenerate egg cells challenges the field to reexamine one of its most sacred dogmas.
Nature Medicine (September 2005)
| Full Text |
Complaints of gender bias compel NIH to revise awards scheme
After a flurry of protests from scientists, this year's winners are likely to be a more diverse bunch.
Nature Medicine (September 2005)
| Full Text |
Hospital closure puts tissue bank in jeopardy
The world's largest tissue repository is without a home after a review panel decided to close the military hospital in Washington DC, where it is based.
Nature (1 September 2005)
| Full Text |
NIH ethics rules come off probation
From the 30th of August NIH researchers are banned from consulting for biotechnology or pharmaceutical companies.
Nature (1 September 2005)
| Full Text |
Expression of interest
Scientists willing to tackle membrane proteins should find opportunities unfolding, as the NIH increases funding to solve membrane protein structures.
Nature (1 September 2005)
| Full Text |
News in brief
India invests in research hub for biotechnology
| Australia reverses student visa cancellations
| Researchers say security law restricts freedoms
| Creativity wins the day in US prize awards
| Incoming ethics chief set to move focus off stem cells
| National Academies plug biotech in Russia
| Banking on cord blood from India
| Light shines on Genentech's vision drug
| Amgen's GDNF headache
| Mutating stem cells provide culture shock
| Scientist-investor links face scrutiny
| Lawsuit loss leaves Merck with murky future
| Journal urges honesty about homeopathy's flop
| NIH aims for online-only grant applications
| Hamster study offers hope of blood test for prions
News Features
Appetite downer awaits approval
A pill that works by putting the hunger induced by cannabis into reverse could jump-start a languishing market for obesity drugs.
Nature (29 September 2005)
| Full Text |
Imaging: The big picture
Over the past ten years, microscopy has been transformed from slice, stain and fix, to the capacity to view living cells in whole organisms in real time.
Nature (29 September 2005)
| Full Text |
Back to school
This month, as most researchers gear up to teach, two scientists are heading into the classroom to learn. Geoff Brumfiel asks why a physicist would want to enrol in biology lessons.
Nature (22 September 2005)
| Full Text |
Research grants: The nightmare before funding
Asked to name one thing they hate about their jobs, many scientists say grant applications. Nature's reporters have asked researchers just why the process is so frustrating, and what can be done to improve matters.
Nature (15 September 2005)
| Full Text |
The problem with potency
Industry hopes to build on recent successes of monoclonal antibodies in oncology and inflammatory disease. But evidence is mounting that the exquisite selectivity and binding capacity of these therapeutics can have unwanted side effects, particularly in autoimmune disease.
Nature Biotechnology (September 2005)
| Full Text |
Stem-cell research: The rocky road to success
Tackling the legal and ethical minefield associated with human embryonic stem-cell research is not for the faint-hearted.
Nature (8 September 2005)
| Full Text |
Revolt in Bethesda
Disheartened by restrictive new rules, researchers at the US National Institutes of Health are speaking out — and several are choosing to jump ship.
Nature Medicine (September 2005)
| Full Text |
Chimp genome: Branching out
The chimp was a great start. But the genomes of our other primate relatives will help to reveal a whole lot more.
Nature (1 September 2005)
| Full Text |
|
